[ad_1]
The 23andMe Genetics Home Testing Company unveiled a beta program that will prompt a subpopulation of its user base to share their lab results, prescribing information and medical history, as well as information gathered from of their genetic test, according to CNBC. This announcement apparently puts 23andMe in competition with Apple's Health Records platform, a hub centered on consumer-centric health records and integrated in more than 16% of US hospitals.
Here is an overview of what sets the 23andMe health record apart from Apple's:
- 23andMe has something important that Apple does not have: genetic data that can support healthcare companies' precision medicine initiatives.23andMe has sold more than 10 million genetic tests, which in fact a leader in the market for DNA testing. And if he is able to keep confidentiality and security issues secret and transform his data caches into a complete set of shared medical data, his data collection will be extremely useful for health care companies. exploring the potential benefits of AI-badisted diagnostic tools and precision medicine tools – which often rely on tons of genetic information.
- But the benefit of Apple's first-mover, its ubiquitous platform and its sustained consumer engagement mean that its platform has a much wider reach than that of 23andMe. In the United States, nearly 190 million phones were used in the United States in February 2019, according to Consumer Intelligence Research Partners. Combine this footprint with the new features of Apple Watch, such as monitoring heart rate irregularities via an electrocardiogram, and integrating data from popular third-party companies and devices, from the monitor from Sweetgreen to OneDrop, and it is clear that Apple is looking for many features. and partners as a way to success. And by making its health platform a home for a host of third-party applications, users are more likely to stay engaged.
The largest image: Despite what it might look like at first glance, I (Zach) think that 23andMe's approach to health data integration is less about data aggregation or consumer access, but more about value transformation. added from its major pharmaceutical partners.
The majority of 23andMe's value comes from its pharmaceutical partnerships – and genetic data is making a huge splash in drug discovery. When pharmaceutical giant GSK invested $ 300 million in 23andMe for exclusive access to consumer data from the genetic testing company, we noticed how this decision could lead to a more focused approach to clinical trials of drugs.
Putting a new drug on the market costs an average of $ 2.6 billion over more than 10 years of development. However, according to an interview with Fortune by GSK's president of research and development, Hal Barron, in Fortune, only about 10 percent of early-stage pharmaceuticals will reach consumers. The same badysis applies here. If GSK can combine the genetic data of 23andMe users with unidentified or synthetic medical information, this could greatly help 23andMe's pharmaceutical partners reduce their financial losses and commercialize new and better medicines.
GSK is not alone in recognizing the potential value of genetic testing for drug development: Regeneron has also collaborated with Geisinger Health to sequence the genetic data of 250,000 patients and a pharmaceutical consortium including Pfizer and AstraZeneca. , which plans to sequence 500,000 patients in the UK, according to The Atlantic.
Interested in the complete story? Here are three ways to get access:
- Register for Digital Health ProBusiness Insider Intelligence's suite of expert products keeps you up-to-date on the people, technologies, trends and businesses shaping the future of healthcare, and is delivered six times a week to your inbox. >> To start
- Subscribe to a Premium Go to Business Insider Intelligence and get immediate access to Digital Health Pro, as well as over 250 other reports that have been the subject of extensive research. As a bonus, you will also have access to all future daily reports and newsletters so you can stay ahead of the curve and benefit personally and professionally. >> Learn more now
- Current subscribers can read the full briefing right here.
Source link
